Recent News 12 : UK makes Its First Reglementation For Industrial Phage Production !

-

Press release

Helping bring phage medicines to UK patients – guidance for industry

Bacteriophages – viruses that selectively fight bacteria – may offer new hope in fighting infections and tackling antimicrobial resistance.

Bacteriophages attaching to bacterium.

The Medicines and Healthcare products Regulatory Agency (MHRA) has today the 4th of June published the UK’s first official guidance to support the safe development and use of phage therapies – treatments that use viruses to target and destroy harmful bacteria.

The guidance aims to help researchers and companies develop phage-based medicines that meet UK safety, quality and efficacy standards, so they can be made available to patients who need them most.

It covers both combined phage products designed for common infections and circulating strains, as well as personalised phage therapies that are tailored for individual patients with rare or highly resistant infections.

For patients, this could mean access to phage treatment when standard-of care-antibiotics fail or cannot be given, for example due to allergies. While some patients in the UK have already received phage therapy under compassionate use – with phages imported from abroad – there are currently no licensed phage medicines on the UK market.

Lawrence Tallon, MHRA Chief Executive, said:

“Some infections are becoming harder to treat when antibiotics are ineffective against them – and patients urgently need new options.

“Phage therapy is one of several promising approaches. This guidance brings together relevant standards to provide clarity for researchers and companies, so they can develop these treatments safely and bring them to the people who need them.

“We’re committed to working with industry to support innovation in this space – without compromising on the robust safety and quality standards that patients rightly expect.

“It’s part of our wider mission to support innovation and make the UK a world leader in life sciences.”

Phage therapies use bacterial viruses – called bacteriophages – that attack specific bacteria without harming human cells. They have received increased interest in recent years as a potential way to treat antibiotic-resistant infections, with over 60,000 serious antibiotic-resistant infections estimated annually in the UK and growing.

The MHRA’s publication sets out how existing UK and international regulatory frameworks apply to phage treatments – from early research through to use in patients. It provides clear, practical advice on what’s needed at each stage of development – whether the goal is a fully licensed product or a treatment used under a clinician’s responsibility for an individual case.

Further detail in the guidance includes: - What evidence is needed to support clinical trials and market authorisation - How to meet standards on quality, safety and manufacturing, including the application of Good Manufacturing Practice (GMP) - How personalised treatments can be developed and supplied - When and how unlicensed phage treatments can be used for individual patients

The 28-page document brings together UK and international regulatory standards in one place, helping innovators clearly understand what’s required – and avoid unnecessary delays.

Julian Beach, MHRA Interim Executive Director of Healthcare Quality and Access, said:

“Developers have told us they need clarity on how phage therapies fit into the UK’s regulatory system. This helps signpost relevant requirements, providing that clarity. We continue to support innovation by working closely with industry and researchers while making sure patients are protected every step of the way.”

The publication supports the UK 2024-2029 National Action Plan to confront AMR and the MHRA’s wider role in enabling innovative, science-led regulation that meets public health need while maintaining high standards for quality and safety.

Dr Colin Brown, deputy director at the UK Health Security Agency, responsible for AMR, said:

“MHRA’s new guidance helps lay the foundations for phage therapy opportunities in the UK. It provides much-needed direction for scientists and researchers working to make this treatment a reality for patients.

“Phage therapy truly has the potential to transform the way we treat bacterial infections, especially as resistance to antibiotics grows. At UKHSA, we’re developing new ways to help increase phage therapy use and research, including a bacteriophage collection where scientists can both access and deposit phages. In time, we hope solutions like phage therapy can become a first-line treatment option.”

The MHRA developed the guidance with input from the Phage Innovation Network, a cross-sector group supported by Innovate UK, and from industry, clinicians and academic researchers.

Frederique Vieville, BEAM Alliance Phage ACT Lead, a European group supporting antimicrobial therapy development, and 5QBD-Biotech Chief Executive, a biotech company focused on bacteriophage therapies, said:

“As difficult-to-treat infections continue to rise, phage therapy is becoming an important complement to existing treatments. Recent steps have been taken by European regulators to outline the regulatory framework for phage-based medicinal products, but developers still need support to navigate it effectively. Clarity about the pathway – tailored to the unique characteristics of phages – is vital to help meet quality, non-clinical, and clinical requirements, and ultimately bring phage-based treatments to patients more efficiently.”

Dr Jason Clark, NexaBiome Director and Chief Scientific Officer, a company developing commercial phage therapies in the UK, said:

“There is an urgent and increasing need for new ways to treat antimicrobial resistant infections, with bacteriophage being at the forefront of recent developments. This new guidance from the MHRA is incredibly forward-thinking and puts the UK in pole position to fully realise the healthcare and commercial benefits of this exiting technology.

“As a Company developing bacteriophage products for human use, this guidance helps us to decrease perceived risks and gives clarity to the regulatory landscape, ultimately enabling us to more readily bring investment into the UK.”

Companies interested in developing bacteriophage treatments can access scientific advice from the MHRA at any stage of development.

References :

From:

Medicines and Healthcare products Regulatory Agency

Published

4 June 2025

Last updated

5 June 2025 — See all updates

(c) https://www.gov.uk/government/news/helping-bring-phage-medicines-to-uk-patients-guidance-for-industry

Comments

Post a Comment

Popular posts from this blog

The Phage Therapy in the spotlight !

-
Image
Bacteriophages: Ancient Predators and the Next Frontier in Medicine In the animated documentary The Deadliest Being on Planet Earth , the Kurzgesagt team delves into the world of bacteriophages—viruses that prey exclusively on bacteria. With vibrant visuals and precise narration, the video introduces viewers to an invisible ecosystem where microscopic hunters orchestrate life-and-death dramas that shape the biosphere. These entities, though virtually unknown to the general public, may soon become central to the future of medicine. At the heart of the video lies a paradox: bacteriophages (or "phages") are among the most abundant biological entities on Earth—outnumbering all other organisms combined—yet their therapeutic potential has been largely sidelined in the antibiotic era. The video outlines the historical trajectory of phage research, spotlighting Félix d’Hérelle’s early 20th-century work and the rise of phage therapy, only to show how it was later eclipsed by the dis...
Read more

History Part 7 : The Rise of Penicillin and the Fall of Phages: A Forgotten Chapter in Medical History

-
Image
Penicillin and the Eclipse of Phage Therapy in Western Medicine (1928–1950) Abstract: The period between the late 1920s and the mid-20th century witnessed a fundamental transformation in antimicrobial therapeutics. Bacteriophage therapy, once a promising solution to bacterial infections, saw increasing use in European clinics during the interwar years. However, the discovery and mass production of penicillin during World War II radically shifted clinical priorities. This article examines the rise of penicillin and the scientific, clinical, and industrial dynamics that led to the displacement of phage therapy in Western medical practice by 1950. Introduction: A Divided Therapeutic Landscape In the interwar period, Western medicine faced a crisis of infectious disease without a universal remedy. While chemical antiseptics and arsenical compounds like Salvarsan were used for certain infections, many remained untreatable. Bacteriophage therapy emerged as a candidate solution, particula...
Read more

History Part 1 : Phage Therapy and its discovery by Felix d'Hérelle

-
Image
Félix d’Hérelle: The Forgotten Father of Phage Therapy Picture of Félix d'Hérelle (Pasteur Institute) A Visionary in the Shadows of History In the annals of microbiology, certain names are carved into stone — Pasteur, Koch, Fleming. But among them, one figure remains unjustly obscured: Félix d’Hérelle, a self-taught microbiologist who, in 1917, discovered the existence of bacteriophages — viruses that infect and destroy bacteria. Through meticulous experimentation and bold clinical application, d’Hérelle not only identified a new biological entity, but pioneered one of the most promising alternatives to antibiotics: phage therapy. A Self-Made Scientist Born in 1873 in Montreal, d’Hérelle had no formal degree in science. Instead, he was an intellectual adventurer — multilingual, well-read, and ferociously curious. After working in Guatemala and Mexico on fermentation and agricultural microbiology, he returned to France where he joined the Pasteur Institute in Paris as an unpaid ...
Read more